期刊文献+

多灶性甲状腺癌的危险因素评估和治疗策略 被引量:8

Risk factors and treatment of multifocal thyroid cancer
下载PDF
导出
摘要 目的探讨多灶性甲状腺癌的危险因素及治疗策略。方法分析116例多灶性甲状腺癌和309例单灶性甲状腺癌的临床特征。采用t检验和χ2检验统计分析,评估多灶性甲状腺癌的危险因素,提出治疗策略。结果多灶组甲状腺癌侵犯包膜率大于单灶组;多灶组淋巴结转移率高、病期晚(P<0.05)。多灶性甲状腺癌中,肿瘤直径>1 cm、病灶数>2个、侵犯包膜、中央区有可疑淋巴结容易出现中央区淋巴结转移(P<0.05)。结论多灶性甲状腺癌比单灶性甲状腺癌病期晚,被膜容易受侵,更容易发生中央区淋巴结转移。多灶性甲状腺癌行全甲状腺切除加中央区淋巴结清扫是安全、必要的。 Objective To explore the risk factors of muhifocal thyroid cancer and its treatment strategies. Methods Clinical features of 116 patients with multifoeal thyroid carcinoma and 309 patients with unifocal thyroid carcinoma were analyzed. T test andχ2 test were used to evaluate the risk factors of multifocal thyroid carcinoma. The possible treatment strategies were proposed. Results Both the capsule invasion rate and the lymph node metastasis rate in the muhifocal group were greater than those in the unifocal group ( P 〈 0.05 ). The stage of disease in the muhifoeal group was later than that in the unifoeal group (P 〈 0.05). In muhifocal papillary thyroid carcinoma with tumor diameter greater than 1 era, the number of lesions greater than 2 and capsule invasion and central suspicious lymph node, it was prone to central lymph node metastasis ( P 〈 0. 05 ). Conclusions The disease stage of multifocal thyroid cancer was later than that of unifoealcaneer, with easy membrane invasion, more prone to lymph node metastasis. Total thyroidectomy plus lymph node dissection would be safe and necessary in patients with multifocal thyroid carcinoma.
出处 《中国眼耳鼻喉科杂志》 2016年第5期322-325,共4页 Chinese Journal of Ophthalmology and Otorhinolaryngology
关键词 甲状腺癌 多发病灶 危险因素 治疗 Thyroid cancer Multiple lesions Risk factors Treatment
  • 相关文献

参考文献15

  • 1北京市疾控中心.2013年北京市卫生与人群健康状况报告[R].2014-06-26.
  • 2Ogilvie JB, Patel KN, Heller KS. Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well- differentiated thyroid microcarcinomas [ J ], Surgery, 2010,148 ( 6 ) : 1222-1226.
  • 3Ciuffreda L, De Martino D, Borrfitto N, et al. Our experience on surgical treatment of papillary thyroid micl,ocarcinoma [ J ]. G Chir, 2011,32(1/2) :41-44.
  • 4Connor MP, Wells D, Schmalbach CE. Yariables predictive ofbilateral occult papillary microcarcinoma following total thyroidectomy [ J ]. Otolaryngol Head Neck Surg,2011,144 (2) :210-215.
  • 5Zhan Q, Ming J, Liu C, et at. Muhifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma [ J ]. Ann Surg Oncol, 2013,20 ( 3 ) : 746 -752.
  • 6Koo BS, Lim HS, Lim YC, et al. Occult eontralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma [ J 1. Ann Surg Oncol,2010,17(4) :1101-1105.
  • 7Kim BY, Sung CFI, Kim JW, et at. Impact of clinicnpatho~ogie factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma[ J]. Yonsei Med J, 2012, 53 (5) :924-930.
  • 8Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid clinicopathological characteristics and implications for treatment in 276 patients [ J ]. Eur J Clin Invest, 2012,42 (6) : 657-664.
  • 9Pelizzo MR, Boschin IM, Toniato A, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid mieroeareinoma (PTMC) : a mono-institutional 12-year experience [ J ]. Nucl Med Commun, 2004,25 ( 6 ) : 547 -552.
  • 10Brmnley MD, Harrison BJ. Papillary mierocarcinoma of the thyroid gland[J]. Br J Surg, 1996, 83(12) :1674-1683.

同被引文献60

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部